Lymphadenectomy in pulmonary metastasectomy

Area of Science:

• Oncology
• Thoracic Surgery
• Surgical Pathology

Background:

• Lymph node (LN) removal during pulmonary metastasectomy is crucial for staging and complete resection, but its routine acceptance is lacking.
• Unexpected lymph node involvement (LNI) rates vary by cancer type (sarcoma <10%, colorectal cancer 20%, renal cell carcinoma 30%) with radical dissection.
• LNI is a negative prognostic factor, often excluding patients from surgery, though some studies show good outcomes despite mediastinal LNI.

Purpose of the Study:

• To evaluate the prognostic significance and impact of lymph node dissection during pulmonary metastasectomy.
• To clarify the benefits and drawbacks of systematic lymphadenectomy in the context of lung metastases resection.

Main Methods:

• Review of studies examining lymph node involvement and dissection during pulmonary metastasectomy.
• Analysis of prognostic factors, including LNI, and outcomes such as survival and recurrence rates.
• Comparison of outcomes with and without radical lymphadenectomy across different cancer types.

Main Results:

• Higher LNI rates are associated with multiple metastases, central lesions, and anatomical resections.
• Some studies report improved survival trends in renal cell carcinoma (RCC) and reduced mediastinal recurrence in colorectal cancer (CRC) post-lymphadenectomy.
• However, many studies show no clear survival benefit, suggesting a potential pseudo-stage migration effect.

Conclusions:

• The true prognostic influence of systematic lymph node dissection in pulmonary metastasectomy remains uncertain.
• While potential benefits like reduced recurrence exist, the overall impact requires further research focusing on survival, local, and lymph node recurrence.
• Future studies should rigorously assess the role of lymphadenectomy to guide clinical practice.